Actively Recruiting
Phase II Study of Orelabrutinib with Zuberitamab for Initial Treatment of Marginal Zone Lymphoma
Led by Li Zhiming · Updated on 2025-05-22
33
Participants Needed
2
Research Sites
108 weeks
Total Duration
AI-Summary
What This Trial Is About
Marginal Zone Lymphoma MZL is a type of B-cell cancer found in areas like the spleen, lymph nodes, and mucosa-associated lymphoid tissues. Researchers are evaluating the combination of two drugs, Orelabrutinib and Zuberitamab, to see how well and how safely they work as the first treatment for MZL. This study is a multi-center, prospective cohort trial focusing on the complete response rate after treatment. Participants receive six cycles of induction therapy with Orelabrutinib and Zuberitamab given together. After this, patients continue with the combination therapy every two cycles for another six cycles, unless the disease worsens or side effects become intolerable. Orelabrutinib is taken orally daily, and Zuberitamab is administered intravenously on specific days of the treatment cycles. During the study, participants undergo imaging tests like CT or MRI scans to measure treatment response. Researchers monitor safety and record outcomes such as the one-year complete response rate and other measures over two years. The study involves regular assessments to track disease status, side effects, and overall health, with participation lasting through the full treatment and follow-up periods.
CONDITIONS
Brief Title
Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL
Research Team
Z
Zhiming Li, professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here